Literature DB >> 19254175

Morphological and quantitative changes of the initial myocardial lymphatics in terminal heart failure.

Alexey Dashkevich1, Wilhelm Bloch, Albert Antonyan, Jochen U W Fries, Hans Joachim Geissler.   

Abstract

BACKGROUND: Terminal heart failure is associated with chronic myocardial edema, which in part is compensated by increased myocardial lymph flow. However, little is known about the impact of terminal heart failure on lymphangiogenesis. The purpose of the study was to investigate the morphological and quantitative changes of the initial myocardial lymphatics in terminal heart failure.
METHODS: Paraffin-embedded left ventricular endomyocardial biopsies, taken during heart transplantation from 7 heart transplant recipients (failing heart) and 8 heart transplant donors (control), were investigated by immunohistostaining and triple immunofluorescence for lymphatic endothelial markers LYVE-1, PROX-1, and VEGFR-3. The vessel density was calculated and the ratio of open versus collapsed vessels was estimated by analyzing randomly selected marked vessels.
RESULTS: The absolute densities of lymph vessels in failing and control myocardium were not significantly different for all investigated markers. The ratio of open LYVE-1 positive lymph vessels in failing heart was significantly higher than in control (64+/-12.5 vs. 44.3+/-9.3, p<0.008). There was no difference for the ratio of open VEGFR-3 vessels between groups (69.0+/-17.5 vs. 70.7+/-17.2). Triple fluorescent immunohistostaining revealed in failing hearts LYVE-1 and PROX-1 positive open vessels, which were VEGFR-3 negative. VEGFR-3 positive, but LYVE-1 and PROX-1 negative vessels could also be seen.
CONCLUSIONS: Myocardial initial lymphatics in patients with terminal heart failure undergo significant morphological changes in comparison to normal hearts. The ratio of open LYVE-1 vessels was higher in failing hearts by no difference in absolute densities for all markers. These findings suggest that appositional growth of initial lymphatics, rather than "de novo" genesis from pluripotent stem cells or sprouting from preexisting venous vessels, may be the predominant mechanism of lymphangiogenesis in terminal heart failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19254175     DOI: 10.1089/lrb.2008.1010

Source DB:  PubMed          Journal:  Lymphat Res Biol        ISSN: 1539-6851            Impact factor:   2.589


  5 in total

1.  Therapeutic lymphangiogenesis after myocardial infarction: vascular endothelial growth factor-C paves the way.

Authors:  Polina Goichberg
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

2.  Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension.

Authors:  LouJin Song; Xian Chen; Terri A Swanson; Brianna LaViolette; Jincheng Pang; Teresa Cunio; Michael W Nagle; Shoh Asano; Katherine Hales; Arun Shipstone; Hanna Sobon; Sabra D Al-Harthy; Youngwook Ahn; Steven Kreuser; Andrew Robertson; Casey Ritenour; Frank Voigt; Magalie Boucher; Furong Sun; William C Sessa; Rachel J Roth Flach
Journal:  Elife       Date:  2020-11-17       Impact factor: 8.140

Review 3.  The wish to cure and the curiosity to investigate - or how I used my life to become a physician-scientist.

Authors:  Jochen Walter Ulrich Fries
Journal:  Front Med (Lausanne)       Date:  2015-03-06

4.  Phenotypically heterogeneous podoplanin-expressing cell populations are associated with the lymphatic vessel growth and fibrogenic responses in the acutely and chronically infarcted myocardium.

Authors:  Maria Cimini; Antonio Cannatá; Gianandrea Pasquinelli; Marcello Rota; Polina Goichberg
Journal:  PLoS One       Date:  2017-03-23       Impact factor: 3.240

5.  Lymphatic endothelial sphingosine 1-phosphate receptor 1 enhances macrophage clearance via lymphatic system following myocardial infarction.

Authors:  Qinyu Li; Caixia Zhou; Kang Zhao; Yunhao Duan; Jinnan Yue; Xiuxiang Liu; Jinjin Wu; Shengqiong Deng
Journal:  Front Cardiovasc Med       Date:  2022-08-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.